Therapeutic Solutions International, Inc. reported successfully generation of a quality control tested Master Cell Bank comprised of its JadiCell universal donor stem cell product. Prior to this, the Company relied on third party manufacturing, which carried significantly more costs as well as potential regulatory uncertainty. The recently generated cells possessed both functional and phenotypic characteristics that the FDA has agreed to in its clearance of the Company to conduct a Phase III clinical trial.

Previously the JadiCells have demonstrated 100% reduction in lethality in COVID19 patients under 85 years old in a double-blind Phase I/II clinical trial.